Bristol-Myers Squibb Company
HealthcareNYSE:BMY · New York Stock Exchange
+$0.23 today
Vol 3.62M · Avg 11.55M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
38.2%
avg 10.5%
ROIC
13.9%
avg 10.7%
ROA
7.8%
avg 4.5%
Analysis
ROE is currently the strongest return metric at 38.2% versus its period average of 10.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher S. Boerner | Chief Executive Officer & Chairman | $5.82M | — | 55 | $156,735.00 | <0.01% |
David V. Elkins | Executive Vice President & Chief Financial Officer | $3.20M | — | 58 | $159,248.00 | <0.01% |
Adam Lenkowsky | Executive Vice President & Chief Commercialization Officer | $3.18M | — | 54 | $19,706.00 | <0.01% |
Greg Meyers | Executive Vice President and Chief Digital & Technology Officer | $2.97M | — | 53 | $44,330.00 | <0.01% |
Karin Shanahan | Executive Vice President, Chief Supply Chain & Operations Officer | $2.42M | — | 61 | $0.00 | <0.01% |
Cristian Massacesi | Executive Vice President, Chief Medical Officer & Head of Development | $2.22M | — | 57 | $39,184.00 | <0.01% |
Ahn Amanda Poole | Executive Vice President & Chief People Officer | — | — | 51 | $23,020.00 | <0.01% |
Cari Gallman | Executive Vice President, General Counsel & Chief Policy Officer | — | — | 46 | $39,184.00 | <0.01% |
Joseph J. Eiden Jr. | Head of Medical Affairs | — | — | 77 | — | — |
Charles E. Triano | SVP & Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$1.85M
Net Sentiment
$1.85M
Net selling
Most Active
Elkins David V
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Elkins David V Direct | Sell | 4.5K | $62.05 | $278,046.05 | |
| Apr 1, 2026 | Elkins David V Direct | Sell | 25.5K | $61.60 | $1,571,970.40 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $1.85M over the last 12 months. That adds up to net selling of $1.85M. Elkins David V was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -5.8% | +11.2% (15yr)3 analysts |
| Revenue | N/A | N/A | -2.0% | +5.4% (15yr)11 analysts |
| Net Income | N/A | N/A | -7.2% | +12.9% (15yr)11 analysts |
| EBIT | N/A | N/A | -2.6% | +1.8% (15yr)11 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.0% over three years. Forward estimates point to Net Income at +12.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Pfizer Inc.
NYSE:PFE
$149.18B
CVS Health Corporation
NYSE:CVS
$129.95B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.63B
GSK plc
NYSE:GSK
$106.57B
Sanofi
NASDAQ:SNY
$106.45B
McKesson Corporation
NYSE:MCK
$94.81B
Elevance Health Inc.
NYSE:ELV
$87.31B
HCA Healthcare, Inc.
NYSE:HCA
$85.73B
Cigna Corporation
NYSE:CI
$78.87B
Zoetis Inc.
NYSE:ZTS
$33.66B
Who manages BMY?
Bristol-Myers Squibb Company (BMY) lists 10 active executives. The top listed executive is Greg Meyers, Executive Vice President and Chief Digital & Technology Officer.
Are BMY insiders buying or selling?
Recent insider activity shows net selling of $6.75M.
Explore More
Continue the stock analysis
Jump to another research area for this company.